Hepatorenal Syndrome – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025

Hepatorenal Syndrome Emerging Therapy and TPP Insights

Thelansis’s “Hepatorenal Syndrome Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Hepatorenal Syndrome Overview

Hepatorenal syndrome (HRS) is a severe complication of advanced liver disease, characterized by functional kidney failure in the absence of intrinsic renal pathology, most often occurring in patients with cirrhosis and portal hypertension, including those with alcoholic hepatitis or other causes of decompensated liver disease. It is precipitated by circulatory changes that lead to renal vasoconstriction, and common triggers include spontaneous bacterial peritonitis, gastrointestinal bleeding, and large‑volume paracentesis without plasma expansion, while sepsis can also provoke HRS through vasoactive mediator release. Clinically, HRS is classified into two types: Type 1, marked by rapid and severe renal decline with a median survival of less than two weeks, and Type 2, which progresses more slowly and is often associated with refractory ascites, with survival typically ranging from several months depending on liver disease severity. Diagnosis requires exclusion of other causes of kidney injury, and while vasoconstrictor therapy with albumin may provide temporary improvement, liver transplantation remains the only definitive treatment offering long‑term survival.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Read more: Hepatorenal Syndrome – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025